Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. IBTROZI appears in 1 tracked Biotech story from September 7, 2026. The tracked stories average 2 original sources each.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. IBTROZI appears in 1 tracked Biotech story from September 7, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering IBTROZI. Shared-story counts are live from our verified record — not editorial picks.
Coverage Highlights Market Divergence
Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
Cramer Calls NUVB 'Pure Speculation'
On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
FDA Grants Fast Track Designation to Safusidenib
Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.
Nuvation Bio's experimental brain cancer drug safusidenib won FDA Fast Track in August 2026, but Jim Cramer on CNBC called the surging stock pure speculation. While IBTROZI showed commercial traction as the most-prescribed new lung cancer treatment in early 2026, most value still hinges on late-stage pipeline data.
Source: aol.com · finance.yahoo.com
IBTROZI is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
